MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.83% | 35.30% | 23.60% | 3.37% | -3.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 164.38% | 94.55% | 36.16% | -1.67% | -16.81% |
| Operating Income | -164.38% | -94.55% | -36.16% | 1.67% | 16.81% |
| Income Before Tax | -175.01% | -56.76% | -4.09% | 24.87% | 31.77% |
| Income Tax Expenses | 199.26% | 367.87% | 444.61% | 284.00% | 159.78% |
| Earnings from Continuing Operations | -175.06% | -57.11% | -4.41% | 24.67% | 31.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -71.40% | -71.81% | -63.51% | -58.73% | -44.46% |
| Net Income | -230.31% | -76.82% | -18.21% | 15.86% | 27.95% |
| EBIT | -164.38% | -94.55% | -36.16% | 1.67% | 16.81% |
| EBITDA | -163.63% | -93.80% | -35.47% | 2.28% | 17.37% |
| EPS Basic | -147.85% | -19.67% | 23.13% | 41.78% | 75.49% |
| Normalized Basic EPS | -185.79% | -28.90% | 16.13% | 36.70% | 72.21% |
| EPS Diluted | -147.85% | -19.67% | 23.13% | 41.78% | 75.49% |
| Normalized Diluted EPS | -185.79% | -28.90% | 16.13% | 36.70% | 72.21% |
| Average Basic Shares Outstanding | 28.17% | 41.78% | 50.71% | 46.49% | 68.93% |
| Average Diluted Shares Outstanding | 28.17% | 41.78% | 50.71% | 46.49% | 68.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
